[6-K] Nanobiotix S.A. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

NanoBiotix S.A. filed a current report stating that a corporate press release has been issued and is included as Exhibit 99.1 and incorporated by reference into the report. The filing is executed on the company’s behalf by Bart Van Rhijn, the Chief Financial Officer.

Insights

Corporate Filings Analyst

The company incorporated a press release into a 6-K and the CFO signed the report.

The filing records that a press release is attached as Exhibit 99.1 and is incorporated by reference, which is a routine mechanism to make public disclosures part of the official report. This does not itself disclose the press release contents or financial metrics within the filing text provided.

The primary dependency for investors is the content of the attached press release; review of Exhibit 99.1 is necessary to assess material impact. Expect immediate market relevance only if the press release contains material news such as financial results, approvals, or transactions.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On October 1, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 1, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: October 1, 2025		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

FAQ

What did Nanobiotix (NBTX) disclose in the 6-K filing?

The filing states a corporate press release is attached as Exhibit 99.1 and incorporated by reference; no additional substantive details appear in the provided text.

Who signed the Nanobiotix 6-K report (NBTX)?

The report was signed on the company’s behalf by Bart Van Rhijn, the Chief Financial Officer.

Is the actual press release text included in the provided content?

No. The provided text references an attached press release as Exhibit 99.1, but the press release content is not included here.

Does this 6-K filing disclose any financial results or transactions for NBTX?

No. The excerpt supplied does not contain earnings, financial tables, or descriptions of transactions; it only notes the incorporation of a press release.

How can I read the press release referenced in the Nanobiotix 6-K?

Obtain Exhibit 99.1 from the full 6-K filing on the issuer’s filings page or the regulatory filings repository to view the press release text.